Evidence map›Paper›PMID 29376148›Full record

ArticleJournal of rare diseases research & treatment2016

Decreasing HMGB1 levels improves outcome of

Linda D Hazlett, Sharon A McClellan, Sandamali A Ekanayaka

Open access · diamondAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of rare diseases research & treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. The Role ofPharmaceutics · 2024
    Review
  2. HMGB1 Antagonist, Box A, Reduces TLR4, RAGE, and Inflammatory Cytokines in the Cornea of P. aeruginosa-Infected Mice.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2018
    Article
  3. Topical Glycyrrhizin Is Therapeutic for Pseudomonas aeruginosa Keratitis.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2018
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Linda D HazlettDepartment of Anatomy and Cell Biology, Wayne State University, School of Medicine, 540 East Canfield Avenue, Detroit, MI 48201, USA.
Sharon A McClellanDepartment of Anatomy and Cell Biology, Wayne State University, School of Medicine, 540 East Canfield Avenue, Detroit, MI 48201, USA.
Sandamali A EkanayakaDepartment of Anatomy and Cell Biology, Wayne State University, School of Medicine, 540 East Canfield Avenue, Detroit, MI 48201, USA.
Wayne State University · US

Funding

VISION RESEARCH--COREP30EY004068 · NEI · WAYNE STATE UNIVERSITY · PI LINDA D HAZLETT · 1985 to 2026
$13.2M
Role of Toll-Like Receptors in Bacterial KeratitisR01EY016058 · NEI · WAYNE STATE UNIVERSITY · PI HAZLETT, LINDA D · 2005 to 2023
$6.0M
NEI NIH HHS P30 EY004068NEI NIH HHS R01 EY016058
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Experimental modelHMGB1KeratitisMicePseudomonas aeruginosa

Identifiers

PMID29376148
PMCPMC5784448
OpenAlexW2796227126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.